Bola John R, Mosher Loren R
Department of Social Work, University of Southern California, MRF-222, Los Angeles, California 90089-0411, USA.
J Nerv Ment Dis. 2003 Apr;191(4):219-29. doi: 10.1097/01.NMD.0000061148.84257.F9.
The Soteria project (1971-1983) compared residential treatment in the community and minimal use of antipsychotic medication with "usual" hospital treatment for patients with early episode schizophrenia spectrum psychosis. Newly diagnosed DSM-II schizophrenia subjects were assigned consecutively (1971 to 1976, N = 79) or randomly (1976 to 1979, N = 100) to the hospital or Soteria and followed for 2 years. Admission diagnoses were subsequently converted to DSM-IV schizophrenia and schizophreniform disorder. Multivariate analyses evaluated hypotheses of equal or better outcomes in Soteria on eight individual outcome measures and a composite outcome scale in three ways: for endpoint subjects (N = 160), for completing subjects (N = 129), and for completing subjects corrected for differential attrition (N = 129). Endpoint subjects exhibited small to medium effect size trends favoring experimental treatment. Completing subjects had significantly better composite outcomes of a medium effect size at Soteria (+.47 SD, p =.03). Completing subjects with schizophrenia exhibited a large effect size benefit with Soteria treatment (+.81 SD, p =.02), particularly in domains of psychopathology, work, and social functioning. Soteria treatment resulted in better 2-year outcomes for patients with newly diagnosed schizophrenia spectrum psychoses, particularly for completing subjects and for those with schizophrenia. In addition, only 58% of Soteria subjects received antipsychotic medications during the follow-up period, and only 19% were continuously maintained on antipsychotic medications.
索泰里亚项目(1971 - 1983年)将社区住院治疗及极少使用抗精神病药物的方式与针对早期发作精神分裂症谱系精神病患者的“常规”医院治疗进行了比较。新诊断为DSM - II精神分裂症的受试者被连续(1971年至1976年,N = 79)或随机(1976年至1979年,N = 100)分配至医院治疗组或索泰里亚治疗组,并随访2年。随后将入院诊断转换为DSM - IV精神分裂症和精神分裂症样障碍。多变量分析以三种方式评估了索泰里亚治疗组在八项个体结局指标和一个综合结局量表上具有同等或更好结局的假设:针对终点受试者(N = 160)、针对完成治疗的受试者(N = 129)以及针对经差异损耗校正后的完成治疗的受试者(N = 129)。终点受试者呈现出有利于实验性治疗的小至中等效应量趋势。在索泰里亚治疗组,完成治疗的受试者具有显著更好的综合结局,效应量为中等(+.47标准差,p =.03)。患有精神分裂症且完成治疗的受试者在索泰里亚治疗中呈现出较大的效应量获益(+.81标准差,p =.02),尤其在精神病理学、工作及社会功能领域。对于新诊断的精神分裂症谱系精神病患者,索泰里亚治疗带来了更好的2年结局,特别是对于完成治疗的受试者以及患有精神分裂症的患者。此外,在随访期间,只有58%的索泰里亚治疗组受试者接受了抗精神病药物治疗,且只有19%持续使用抗精神病药物。